1. Show article details.

    BRIEF-Reata Pharmaceuticals Says Ongoing Trials In Patients With Pulmonary Arterial Hypertension Stopped Due To High Risk Of COVID-19 To These Patients

    Reuters – 5:48 PM ET 03/30/2020

    Reata Pharmaceuticals Inc (RETA): * REATA PHARMACEUTICALS (RETA) - ONGOING TRIALS IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION STOPPED DUE TO HIGH RISK OF COVID-19 TO THESE PATIENTS. * REATA PHARMACEUTICALS (RETA) - SECOND YEAR OF PHASE 3 CARDINAL TRIAL CONTINUING AS PLANNED. * REATA PHARMACEUTICALS (RETA) - ENROLLMENT OF NEW PATIENTS IN FALCON TRIAL TEMPORARILY PAUSED.

  2. Show article details.

    Reata Pharmaceuticals Provides Update on the Impact of the COVID-19 Pandemic on Its Clinical Studies and Business Operations

    GlobeNewswire – 4:05 PM ET 03/30/2020

    ONGOING TRIALS IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION STOPPED DUE TO HIGH RISK OF COVID-19 TO THESE PATIENTS SECOND YEAR OF PHASE 3 CARDINAL TRIAL CONTINUING AS PLANNED ENROLLMENT OF NEW PATIENTS IN FALCON TRIAL TEMPORARILY PAUSED PLANO, Texas, March 30, 2020 -- Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of s...

  3. Show article details.

    BRIEF-Reata Pharmaceuticals Reports Q4 Non-Gaap Loss Per Share $1.59

    Reuters – 4:12 PM ET 02/19/2020

    Reata Pharmaceuticals Inc (RETA): * Q4 NON-GAAP LOSS PER SHARE $1.59. * Q4 GAAP LOSS PER SHARE $5.91. * Q4 REVENUE $2.7 MILLION. * Q4 REVENUE ESTIMATE $6.9 MILLION -- REFINITIV IBES DATA. * Q4 EARNINGS PER SHARE ESTIMATE $-3.90 -- REFINITIV IBES DATA.

  4. Show article details.

    Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2019 Financials and Provides an Update on Development Programs

    GlobeNewswire – 4:01 PM ET 02/19/2020

    Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full year ended December 31, 2019, and provided an update on the Company’s business and product development programs.

  5. Reata Pharmaceuticals stock price target raised to $290 from $275 at Ladenburg Thalmann

    MarketWatch – 7:37 AM ET 02/14/2020
  6. Show article details.

    Reata Pharmaceuticals, Inc. to Report Fourth Quarter and Full Year 2019 Financials and to Provide an Update on Development Programs on February 19, 2020

    GlobeNewswire – 4:01 PM ET 02/12/2020

    Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development programs post-market on February 19, 2020. Reata’s management will host a conference call on February 19, 2020, at 4:30 p.m. ET.

  7. Show article details.

    Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    GlobeNewswire – 11:15 AM ET 11/18/2019

    Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 2,760,000 shares of its Class A common stock, which included 360,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $183.00 per share.

  8. Show article details.

    Reata Pharmaceuticals, Inc. Announces Pricing of Upsized Class A Common Stock Public Offering

    GlobeNewswire – 7:15 PM ET 11/13/2019

    Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 2,400,000 shares of its Class A common stock at a price to the public of $183.00 per share. Citigroup, Jefferies, SVB Leerink and Stifel are acting as the joint book-running managers for the offering.

  9. Show article details.

    Reata Pharmaceuticals, Inc. Announces Proposed Public Offering of Class A Common Stock

    GlobeNewswire – 4:01 PM ET 11/12/2019

    Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced its intention to offer and sell 2,000,000 shares of its Class A common stock in an underwritten public offering pursuant to an existing shelf registration statement. Citigroup, Jefferies, SVB Leerink and Stifel are acting as the joint book-running managers for the offering.

  10. Show article details.

    Reata Pharmaceuticals, Inc. Announces Third Quarter 2019 Financial Results and an Update on Development Programs

    GlobeNewswire – 6:45 AM ET 11/12/2019

    Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2019, and provided an update on the Company’s business and product development programs.

  11. Show article details.

    Reata Announces Positive Topline Year One Results From Pivotal Phase 3 Cardinal Study of Bardoxolone Methyl in Patients With Alport Syndrome

    GlobeNewswire – 4:02 PM ET 11/11/2019

    ACHIEVED PRIMARY ENDPOINT OF STATISTICALLY SIGNIFICANT IMPROVEMENT IN EGFR COMPARED TO PLACEBO AFTER 48 WEEKS OF TREATMENT ACHIEVED KEY SECONDARY ENDPOINT OF STATISTICALLY SIGNIFICANT IMPROVEMENT IN RETAINED EGFR COMPARED TO PLACEBO AFTER 48 WEEKS OF TREATMENT AND WITHDRAWAL OF DRUG FOR 4 WEEKS CONFERENCE CALL WITH MANAGEMENT SCHEDULED FOR NOVEMBER  12, 2019 AT 8:00 AM ET PLANO, Texas, Nov. 11,...

  12. Show article details.

    Reata Pharmaceuticals, Inc. to Report Third Quarter 2019 Financial Results and to Provide an Update on Development Programs on November 12, 2019

    GlobeNewswire – 6:45 AM ET 11/05/2019

    Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development programs on November 12, 2019, before the market opens. Reata’s management with host a conference call at at 8:00 a.m. ET.

  13. Show article details.

    Reata Announces Positive Topline Results from the MOXIe Registrational Trial of Omaveloxolone in Patients with Friedreich’s Ataxia

    GlobeNewswire – 4:01 PM ET 10/14/2019

    ACHIEVED PRIMARY ENDPOINT OF STATISTICALLY SIGNIFICANT IMPROVEMENT IN MFARS COMPARED TO PLACEBO AFTER 48 WEEKS OF TREATMENT CONFERENCE CALL WITH MANAGEMENT SCHEDULED FOR OCTOBER 15, 2019, AT 8:00 AM ET IRVING, Texas, Oct. 14, 2019 -- Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, announced today that the registrational Part 2 portion of the MOXIe Phase 2 trial of omave...

  14. Show article details.

    Reata Pharmaceuticals, Inc. Announces Presentations at the American Society for Nephrology Kidney Week 2019

    GlobeNewswire – 10:00 AM ET 10/11/2019

    Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced that three abstracts highlighting clinical and nonclinical data for bardoxolone methyl will be presented at the American Society of Nephrology Kidney Week 2019 Annual Meeting being held from November 5 – 10, at the Walter E. Washington Convention Center in Washington, D.C. Abstracts selected for presentatio...

  15. Show article details.

    Reata Pharmaceuticals Reacquires Rights From AbbVie to Develop and Commercialize Bardoxolone Methyl, Omaveloxolone, and All Next-Generation Nrf2 Activators

    GlobeNewswire – 6:45 AM ET 10/10/2019

    Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced the reacquisition of development, manufacturing and commercialization rights concerning its proprietary Nrf2 activator product platform originally licensed to AbbVie, Inc. for territories outside of the United States with respect to bardoxolone methyl and worldwide with respect to omaveloxolone and other ne...

Page:

Today's and Upcoming Events

  • May
    11

    RETA to announce Q1 earnings (Unconfirmed)

Past Events (last 90 days)

  • Feb
    19

    RETA announced Q4 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.